Founded in 1997, Se-cure Pharmaceuticals Ltd. is a clinical stage technology-driven pharmaceutical company focused on developing safe and effective therapeutic solutions, derived from botanical sources.

Implementing proprietary botanical drug development and scaling technologies, we are able to introduce novel biochemical agents characterized by functionally selective mechanisms of action in the target tissues.

In developing drugs from Botanical Sources, Se-cure implements a unique methodology, in accordance with the USFDA botanical drug development guideline. By using OTC pilot sales of its botanical therapeutics, Se-cure has the ability to establish large scale human and post marketing data, providing both efficacy and safety data, substantially increasing the developed agent's probability of success in phase III studies, towards a New Drugs Approval (NDA).

Se-cure's current pipeline comprises 6 botanical drug candidates, targeting women's health and osteoporosis management, benign hyperplasia (BPH) management (male health), burn injury management and dental bone rejuvenation. The botanical drug candidates that Se-cure develops are backed with robust intellectual property strategy.

Standing up to the challenges of large scale manufacturing of botanical pharmaceuticals, Se-cure owns and operates a state of the art cGMP pharmaceutical manufacturing campus, BVQI certified for ISO 9001-2008, and ISO 14001-2004.